The Preferred Premedication Order to Prevent Infusion Reactions in Patients with Breast Cancer Receiving Pertuzumab Plus Trastuzumab and Docetaxel

Aims:Pertuzumab plus trastuzumab and docetaxel is a standard regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the metastatic, adjuvant, neoadjuvant settings. Infusion reaction represents one of common side effects anti-HER2 agents. There no premedication to prevent infusion reactions, although antihistamines, acetaminophen, and/or corticosteroids are often used this purpose. This study evaluated ability induction reactions patients receiving pertuzumab, trastuzumab, docetaxel.
 Methods: retrospective, single-institute assessed 72 women with HER2-positive early who received between November 2018 April 2021. Thirty-six consisting oral acetaminophen prior pertuzumab administration dexamethasone D-chlorpheniramine maleate intravenously (previous regimen). dexamethasone, sequentially (current regimen).
 Results: The rates after initial injection were 55.6 16.7% previous current regiment groups, respectively (p = 0.001). Trastuzumab more frequently caused than docetaxel. Chills, vomiting, nausea major symptoms reactions.
 Conclusion: Premedication featuring upfront use targeted agents significantly prevented reactions.